News

Deal Announcements

Gliknik Groks Second Venture Capital Round

Wednesday, October 10, 2012 5:59:00 AM PDT | VentureDeal
   Baltimore, Maryland  --  Biotechnology company Gliknik has garnered $4.9 million in its second institutional venture capital funding.

Gliknik is developing new therapies for patients with cancer and autoimmune, inflammatory diseases by modulating the immune system.

Baxter Ventures led the round, which included other undisclosed investors.

The company said it would use the financing to advance its lead compound.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1